Abstracts tagged "Antibodies"

Abstract Number: 633 • 2015 ACR/ARHP Annual Meeting
Anti-Centromere Antibodies Are Associated with More Severe Exocrine Glandular Dysfunction in Primary Sjögren’s Syndrome: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹, Leah Medrano² and Mara McAdams-Demarco³, ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD, ³Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD
Background/Purpose: Anti-centromere antibodies (ACA) define a subgroup of Sjögren’s syndrome (SS) patients who are often older, have more frequent Raynaud’s phenomenon, and a lower frequency…
Abstract Number: 2951 • 2015 ACR/ARHP Annual Meeting
Anti-NR2 Antibody and Blood-Brain Barrier Disruption in Systemic Lupus Erythematosus Patients with Cognitive Dysfunction
Gaurav Gulati¹, Philip Iffland², Damir Janigro², Bin Zhang³ and Michael Luggen⁴, ¹Division of Immunology, Allergy and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Cleveland Clinic Lerner College of Medicine, Cleveland, OH, ³Cincinnati Children's Hospital and Medical Center, Cincinnati, OH, ⁴Division of Immunology, University of Cincinnati Medical Center, Cincinnati, OH
Background/Purpose: Cognitive Dysfunction (CD) is one of the most common manifestations of neuropsychiatric SLE (NPSLE) and one of the most devastating. The pathogenesis of CD…
Abstract Number: 635 • 2015 ACR/ARHP Annual Meeting
Seronegative Sjögren’s Syndrome Is Associated with a Higher Frequency of Patient-Reported Neuropathic Pain: An Analysis of the Sjögren’s International Collaborative Clinical Alliance Cohort
Alan N. Baer¹ and Julius Birnbaum², ¹Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ²Medicine (Rheumatology), Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Patients with Sjögren’s syndrome (SS) and negative SSA/SSB serology (ie. seronegative SS) have phenotypic characteristics different than seropositive ones, and thus may constitute a…
Abstract Number: 3112 • 2015 ACR/ARHP Annual Meeting
Incidence of Anti-Drug Antibodies in Rheumatoid Arthritis Patients Treated with Adalimumab, Etanercept, or Infliximab in a Real-World Setting
RJ Moots¹, Ricardo Xavier², Chi Chiu Mok³, Mahboob U Rahman⁴, Wen-Chan Tsai⁵, Mustafa Al Maini⁶, Karel Pavelka⁷, Ehab Mahgoub⁸, Sameer Kotak⁹, Joan Korth-Bradley¹⁰, Ronald Pedersen¹¹, Linda Mele⁸, Qi Shen⁸ and Bonnie Vlahos⁸, ¹Department of Musculoskeletal Biology, University of Liverpool, Liverpool, United Kingdom, ²Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil, ³Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong, ⁴Perelman School of Medicine, University of Pennsylvania, Philadephia, PA, ⁵Kaohsiung Medical University, Kaohsiung, Taiwan, ⁶Rheumatology, Allergy and Clinical Immunology Division, Mafraq Hospital, Abu Dhabi, United Arab Emirates, ⁷Charles University, Prague, Czech Republic, ⁸GIPB - Clinical Sciences, Pfizer, Collegeville, PA, ⁹Global Health and Value, Pfizer, New York, NY, ¹⁰GIPB- Clinical Sciences, Pfizer, Collegeville, PA, ¹¹Department of Biostatistics, Pfizer, Collegeville, PA
Background/Purpose: Treatment with biologics can elicit unwanted immune responses such as antidrug antibodies (ADA), which may decrease their clinical efficacy and increase adverse events. However,…
Abstract Number: 809 • 2015 ACR/ARHP Annual Meeting
Patients with SLE Who Are Anti-Factor Xa IgG Positive Are Less Likely to Have Atherosclerotic Plaque
Claire-Louise Murphy¹, Sara Croca¹, Bahar Artim-Esen², Laura Hanns³, Charis Pericleous¹, Thomas McDonnell¹, Yiannis Ioannou⁴, David A. Isenberg¹, Anisur Rahman¹ and Ian Giles⁵, ¹Rayne Institute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom, ²Department of Internal Medicine, Division of Rheumatology, Istanbul University, Istanbul Faculty of Medicine, Istanbul, Turkey, ³Rheumatology, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁴Rayne Institute, Arthritis Research UK Centre for Adolescent Rheumatology, UCL Division of Medicine, London, United Kingdom, ⁵Rayne Intitiute, Centre for Rheumatology Research, UCL Division of Medicine, London, United Kingdom
Background/Purpose: Patients with SLE have an increased risk of cardiovascular disease (CVD), which is not fully explained by traditional risk factors and may be mediated…
Abstract Number: 823 • 2015 ACR/ARHP Annual Meeting
Anti-IFI16 Antibodies in Scleroderma Are Associated with Digital Gangrene
Zsuzsanna McMahan¹, Ami A. Shah², Dhananjay Vaidya³, Fredrick M. Wigley⁴, Antony Rosen⁵ and Livia Casciola-Rosen⁶, ¹Rheumatology, Johns Hopkins University, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Medicine, School of Medicine, Johns Hopkins, Baltimore, MD, ⁴Rheum Div/Mason F Lord, Johns Hopkins University School of Medicine, Baltimore, MD, ⁵Mason Lord Bldg Ctr Tower, Johns Hopkins University, School of Medicine, Baltimore, MD, ⁶Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Our aim was to examine and confirm the association between anti-IFI16 antibodies and clinical features of scleroderma. Methods: Sera from a discovery sample…
Abstract Number: 2008 • 2014 ACR/ARHP Annual Meeting
Personalized Risk Education for Rheumatoid Arthritis Improves Self-Perceived Risk Accuracy and Risk Factor Knowledge in First-Degree Relatives
Jeffrey A. Sparks¹, Maura D. Iversen^1,2,3, Rachel Miller Kroouze^1,4, Nellie A. Triedman¹, Taysir G. Mahmoud¹, Sarah S. Kalia⁴, Michael L. Atkinson⁵, Robert C. Green⁴ and Elizabeth W. Karlson¹, ¹Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ²Department of Physical Therapy, Movement & Rehabilitation Sciences, Northeastern University, Boston, MA, ³Department of Women's and Children's Health, Karolinska Institutet, Stockholm, Sweden, ⁴Division of Genetics, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, ⁵Channing Division of Network Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA
Background/Purpose Having a first-degree relative (FDR) with RA increases personal RA risk by four-fold. Other RA risk factors include demographics, genetics, auto-antibodies, and behaviors. We…
Abstract Number: 1703 • 2014 ACR/ARHP Annual Meeting
An Association of Anti-PM/Scl Antibody Reactivity with Risk of Malignancy in Scleroderma
Cosimo Bruni¹, Ana Lages², Hitesh Patel³, Jennifer Harvey³, Voon H. Ong⁴, Marco Matucci-Cerinic¹, Emma C. Derrett-Smith⁵ and Christopher P Denton⁶, ¹Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy, ²Affiliation servicio de Medicina Interna, Hospital De Braga, Braga, Portugal, ³Department of Clinical Immunology, Royal Free Hospital, London, United Kingdom, ⁴Centre for Rheumatology and Connective Tissue Diseases, UCL Medical School Royal Free Campus, London, United Kingdom, ⁵Centre for Rheumatology and Connective Tissue Diseases,, UCL Medical School Royal Free Campus, London, United Kingdom, ⁶Centre for Rheumatology and Connective Tissue Disease, UCL Medical School Royal Free Campus, London, United Kingdom
Association of anti-PM/Scl antibody with risk of malignancy in scleroderma. C. Bruni¹, A. Lages², H. Patel3, J. Harvey3, V. Ong4, M. Matucci-Cerinic¹, E. Derrett-Smith4, C.P.…
Abstract Number: 1620 • 2014 ACR/ARHP Annual Meeting
Antibody to Malondialdehyde-Acetaldehyde Adducts (MAA) As a Potential Biomarker of Inflammation in Systemic Lupus Erythrematosus (SLE)
Andy Hollins¹, Michael Duryee², Michelene Hearth-Holmes³, Ted R. Mikuls¹, Zhixin Zhang⁴, Kaihong Su⁵ and Geoffrey M. Thiele⁶, ¹University of Nebraska Medical Center, Omaha, NE, ²Internal Medicine, University of Nebraska Medical Center, Omaha, NE, ³Internal Medicine/Rheumatology Division, University of Nebraska Medical Center, Omaha, NE, ⁴Department of Pathology and Microbiology, University of Nebraska Medical Center, Omaha, NE, ⁵Eppley Cancer Institute, University of Nebraska Medical Center, Omaha, NE, ⁶Internal Medicine, Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE
Background/Purpose Studies have shown that malondialdehyde-acetaldehyde (MAA) is formed as a result of lipid peroxidation of cellular membranes and is capable of binding or adducting…
Abstract Number: 1309 • 2014 ACR/ARHP Annual Meeting
Does Anti-C1q Antibody Have Diagnostic and Prognostic Roles in Childhood – Onset Systemic Lupus Erythematosus?
Thaschawee Arkachaisri¹, Joo Guan Yeo², Justin Hung Tiong Tan³, Sook Fun Hoh⁴, Lena Das³ and Jing Yao Leong², ¹Rheumatology & Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ²Children Intensive Care Unit (CICU), KK Women's and Children's Hospital, Singapore, Singapore, ³Rheumatology and Immunology, KK Women's and Children's Hospital, Singapore, Singapore, ⁴Nursing, KK Women's and Children's Hospital, Singapore, Singapore
Background/Purpose: Biomarkers proven to be effective in aSLE patients may not directly apply to cSLE unless validation is done. Existing evidences have shown immunopathogenic roles…
Abstract Number: 1248 • 2014 ACR/ARHP Annual Meeting
Serologic and Clinical Overlap Between Sarcoidosis and the Rheumatic Autoimmume Diseases
Sabrina Qazi¹ and Marie Claire Maroun², ¹Internal Medicine-Rheumatology, Wayne State University, Detroit, MI, ²Rheumatology, Wayne State University, Detroit, MI
Background/Purpose Sarcoidosis is a systemic inflammatory disorder of unknown etiology, characterized pathologically by noncaseating epithelioid cell granulomas, primarily affecting the lungs, the eye, the skin,…
Abstract Number: 730 • 2014 ACR/ARHP Annual Meeting
Prediction of Cardiac and Vascular Events in Systemic Sclerosis: Input from Endothelin-1 Type a Receptor Antibodies
Jerome Avouac¹, Gabriela Riemekasten², Christophe Meune³, Barbara Ruiz⁴ and Yannick Allanore¹, ¹Paris Descartes University, Rheumatology A Department and INSERM U1016, Cochin Hospital, Paris, France, ²Charité University Hospital and German Rheumatism Research Centre, a Leibniz Institute, Berlin, Germany, ³Paris 13 University, University Hospital of Paris-Seine-Saint-Denis, Cardiology Department, Bobigny, France, ⁴Paris Descartes University, INSERM U1016, Institut Cochin, Sorbonne Paris Cité, Paris, France
Background/Purpose: Cardiac and peripheral microvascular alterations are key features of systemic sclerosis (SSc). We have previously reported that angiogenic markers can predict the cardiovascular outcomes…
Abstract Number: 320 • 2014 ACR/ARHP Annual Meeting
Autoantibodies in Juvenile Systemic Sclerosis
Katharine Moore^1,2, J. Lee Nelson^3,4, Marvin J. Fritzler⁵, Marisa S. Klein-Gitelman⁶, Ann M. Reed⁷, Tzielan C. Lee⁸ and Anne M. Stevens^1,9, ¹Pediatrics, University of Washington, Seattle, WA, ²Pediatric Rheumatology, Seattle Children's Hospital, Seattle, WA, ³University of Washington, Seattle, WA, ⁴Fred Hutchinson Cancer Research Center, Seattle, WA, ⁵Mitogen Advanced Diagnostics Laboratory, Faculty of Medicine, University of Calgary, Calgary, AB, Canada, ⁶Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, ⁷Rheumatology, Mayo Clinic, Rochester, MN, ⁸Pediatric Rheumatology, Stanford University School of Medicine, Stanford, CA, ⁹Center for Immunity and Immunotherapies, Seattle Children's Research Institute, Seattle, WA
Background/Purpose: There are no known biomarkers for organ involvement, response to therapy, or prognosis in juvenile systemic sclerosis (jSSc). In adults with systemic sclerosis, a…
Abstract Number: 2924 • 2014 ACR/ARHP Annual Meeting
Clinical Utility of Random Anti-TNF Drug Level Testing and Measurement of Anti-Drug Antibodies on Long-Term Treatment Response in Rheumatoid Arthritis
Meghna Jani¹, Hector Chinoy^1,2, Richard B. Warren³, Christopher E.M Griffiths³, Ann W. Morgan⁴, Anthony G. Wilson⁵, Kimme L. Hyrich¹, John Isaacs⁶, Darren Plant^1,2 and Anne Barton^1,7, ¹Centre for Musculoskeletal Research, University of Manchester, Manchester, United Kingdom, ²NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academy of Health Sciences, Manchester, United Kingdom, ³Dermatology Centre, University of Manchester, Manchester, United Kingdom, ⁴Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ⁵Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland, ⁶Institute of Cellular Medicine, University of Newcastle, Newcastle, United Kingdom, ⁷NIHR Manchester Musculoskeletal Biomedical Research Unit, Manchester Academic Health Science Centre, Manchester, United Kingdom
Background/Purpose Up to 40% of RA patients on anti-TNF treatment fail to respond either due to primary inefficacy or loss of response. One explanation is…
Abstract Number: 2771 • 2014 ACR/ARHP Annual Meeting
PET-CT Imaging and Association of Ferritin Autoantibodies in Polymyalgia Rheumatica
Niklas Thomas Baerlecken¹, Torsten Witte², Marco Amedeo Cimmino³ and Dario Camellino⁴, ¹Clinical Immunology and Rheumatology, MD, Hannover, Germany, ²Medical School Hannover, MD, Hanover, Germany, ³Clinica Reumatologica, Università di Genova, Genova, Italy, ⁴Dipartimento Medicina Interna, Clinica Reumatologica, Genova, Italy
Background/Purpose Previously we described antibodies against ferritin heavy chain peptide (anti-FHCP) in sera of patients with giant cell arteritis (GCA) and/or polymyalgia rheumatic (PMR) before…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].